SETDB1 and Huntington disease: In the current study, we verified that APQ is a bona fide epigenetic drug, improving motor function in the HD mouse model through the recovery of neuronal activity by reducing SETDB1 activity and H3K9me3-dependent heterochromatin plasticity.